Scholarlink

Objective <p>Chronic inflammation is characterized by excessive cytokine production and macrophage infiltration, contributing to disease progression. This study aimed to enhance the therapeutic efficacy and local delivery of carvacrol (CVL), a natural PPAR-γ activator with anti-inflammatory properties, through the development of a poly(lactic-co-glycolic) acid (PLGA)-based nanoparticle delivery system with hyaluronic acid (HA)-dependent macrophage targeting.</p> Methods <p>Poly(lactic-co-glycolic) acid (PLGA)-based nanoparticles encapsulating CVL (CP NPs) were prepared and coated with 1.5% w/v hyaluronic acid (HA) to form CHP NPs for CD44 receptor-mediated targeting of pro-inflammatory macrophages. Physicochemical characterization, encapsulation efficiency, and drug release profile were evaluated. Cellular uptake and cytokine modulation were assessed in lipopolysaccharide-stimulated macrophages.</p> Results <p>CP NPs exhibited a size of 155 ± 3&#xa0;nm and a zeta potential of -57.7 ± 1.3&#xa0;mV, while HA coating yielded CHP NPs with a size of 225 ± 18&#xa0;nm and a zeta potential of -25.5 ± 0.3&#xa0;mV. Encapsulation efficiency and loading capacity reached 91 ± 5% and 26 ± 7%, respectively. HA coating enhanced nanoparticle internalization by 41% compared to uncoated NPs. A sustained release profile was achieved, with 50 ± 13% of CVL released over 21&#xa0;days. In macrophages, CHP NPs increased anti-inflammatory cytokines IL-1ra (+ 258%), IL-4 (+ 260%), and IL-10 (+ 40%), while reducing pro-inflammatory cytokines IL-1α (-25%), IL-1β (-36%), and TNF-α (-36%) relative to untreated cells.</p> Conclusions <p>HA-coated PLGA nanoparticles effectively delivered CVL, enhancing macrophage targeting and promoting an anti-inflammatory response. This platform offers a promising strategy for treating chronic inflammation-related diseases.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Enabling Anti-inflammatory Activity through Hyaluronan-coated PLGA Nanoparticles Loaded with Carvacrol

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月13日

查看全文
  • Saniya Salathia,
  • Dimitrios Agas,
  • Maria Rosa Gigliobianco,
  • Luca Boldrini,
  • Alessia Cappelli,
  • Cristina Casadidio,
  • Piera Di Martino,
  • Maria Giovanna Sabbieti,
  • Roberta Censi

摘要

Objective

Chronic inflammation is characterized by excessive cytokine production and macrophage infiltration, contributing to disease progression. This study aimed to enhance the therapeutic efficacy and local delivery of carvacrol (CVL), a natural PPAR-γ activator with anti-inflammatory properties, through the development of a poly(lactic-co-glycolic) acid (PLGA)-based nanoparticle delivery system with hyaluronic acid (HA)-dependent macrophage targeting.

Methods

Poly(lactic-co-glycolic) acid (PLGA)-based nanoparticles encapsulating CVL (CP NPs) were prepared and coated with 1.5% w/v hyaluronic acid (HA) to form CHP NPs for CD44 receptor-mediated targeting of pro-inflammatory macrophages. Physicochemical characterization, encapsulation efficiency, and drug release profile were evaluated. Cellular uptake and cytokine modulation were assessed in lipopolysaccharide-stimulated macrophages.

Results

CP NPs exhibited a size of 155 ± 3 nm and a zeta potential of -57.7 ± 1.3 mV, while HA coating yielded CHP NPs with a size of 225 ± 18 nm and a zeta potential of -25.5 ± 0.3 mV. Encapsulation efficiency and loading capacity reached 91 ± 5% and 26 ± 7%, respectively. HA coating enhanced nanoparticle internalization by 41% compared to uncoated NPs. A sustained release profile was achieved, with 50 ± 13% of CVL released over 21 days. In macrophages, CHP NPs increased anti-inflammatory cytokines IL-1ra (+ 258%), IL-4 (+ 260%), and IL-10 (+ 40%), while reducing pro-inflammatory cytokines IL-1α (-25%), IL-1β (-36%), and TNF-α (-36%) relative to untreated cells.

Conclusions

HA-coated PLGA nanoparticles effectively delivered CVL, enhancing macrophage targeting and promoting an anti-inflammatory response. This platform offers a promising strategy for treating chronic inflammation-related diseases.

Graphical Abstract